☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
neurogenic detrusor overactivity
The US FDA Approves New Indication and Formulation for Astellas' Myrbetriq
March 26, 2021
Astellas Reports the US FDA's Acceptance of Priority Review for its NDO Therapy
January 7, 2021
AbbVie Reports the US FDA's Acceptance of BOTOX's sBLA for Pediatric Patients with Neurogenic Detrusor Overactivity
June 23, 2020
Astellas' VESIcare LS (solifenacin succinate) Receives the US FDA's Approval to Treat Neurogenic Detrusor Overactivity (Ndo) In Pe...
May 27, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.